DNTH312 / Dianthus Therap - LARVOL DELTA

Dianthus Therapeutics, Inc. today announced DNTH312, an investigational, first-in-class, extended half-life bifunctional fusion protein that combines claseprubart and TACI. (The Manila Times) - "DNTH312 demonstrated comparable in vitro potency and aC1s inhibition to claseprubart and similar Ig reductions to povetacicept in non-human primates...DNTH312 demonstrated comparable in vitro potency and aC1s inhibition to claseprubart across several functional assays of Classical Pathway inhibition. Additionally, DNTH312 is enhanced with YTE half-life extension technology, and has a similar NHP half-life (22 days) to claseprubart. DNTH312 also demonstrated a similar depth of IgM, IgA, and IgG reduction following a single dose in NHPs compared to povetacicept...DNTH312 aims to be Phase 1 ready by YE'27."

New P1 trial • Preclinical • Immunology